医学
阿替唑单抗
肝细胞癌
肿瘤科
贝伐单抗
内科学
癌症
免疫疗法
重症监护医学
无容量
化疗
作者
Xiu Chen,Liqiu Kou,Xiulan Xie,Song Su,Jun Li,Yaling Li
出处
期刊:Immunology
[Wiley]
日期:2024-01-12
卷期号:172 (1): 21-45
被引量:1
摘要
The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this class of drugs has shown good therapeutic prospects. For example, atezolizumab in combination with bevacizumab has been approved as first-line treatment for advanced HCC due to significant efficacy. However, sensitivity to ICI therapy varies widely among HCC patients. Therefore, there is an urgent need to search for determinants of resistance/sensitivity to ICIs and to screen biomarkers that can predict the efficacy of ICIs. This manuscript reviews the research progress of prognostic biomarkers associated with ICIs in HCC in order to provide a scientific basis for the development of clinically individualised precision medication regimens.
科研通智能强力驱动
Strongly Powered by AbleSci AI